Many rheumatology researchers share concerns about the landscape for future opportunities, given recent pressures from the current presidential administration. These may make an already challenging environment even more difficult for academic physicians to successfully navigate. But many in the field will persevere despite obstacles, driven by the need to deepen understanding of these conditions and…
Based on research showing improved signs and symptoms of systemic sclerosis in patients taking cilnidipine vs. placebo, the FDA granted orphan drug designation for the agent.
‘Measuring patient-reported outcomes (PROs) is an important component of high-quality, patient-centered care, but integration of PROs into clinic can be challenging,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘Luckily, tools exist to help us realize this vital aspect of patient care.’ The ACR’s quality measures for care include gauging disease activity and…
The FDA approved an oral solution of colchicine for the prevention of gout flare in adults. Its dosage can be easily adjusted on the basis of patient needs.
Marked by their passionate support of Taylor Swift, several rheumatologists, rheumatology professionals and ACR staff who identify as Swifties spoke to us about their in-depth knowledge of Swift’s music and active engagement in fan discussions and events.
Guest columnists Dr. Daniel Solomon & Dr. Andrew Concoff discuss the potential of technology, such as mobile health apps, to enhance remote care & improve access for underserved patients.
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
With the U.S. Food & Drug Administration’s approval in 2014 of asfotase alfa for replacement of tissue-non-specific alkaline phosphatase (TNSALP or TNAP) in juvenile-onset hypophosphatasia (HPP), rheumatologists have a responsibility to recognize the more subtle manifestations of this condition in adults to avoid missed treatment opportunities for fractures, dental loss and musculoskeletal pain. Hypophosphatasia is…
At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.